Literature DB >> 30562068

Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes.

Alexander C Fanaroff1,2, Derek Cyr2, Megan L Neely2, Jeffery Bakal3, Harvey D White4, Keith A A Fox5, Paul W Armstrong3, Renato D Lopes1,2, E Magnus Ohman1,2, Matthew T Roe1,2.   

Abstract

Background Cardiovascular clinical trials have traditionally incorporated separate time-to-first-event analyses for their primary efficacy and safety comparisons, but this framework has a number of limitations, including limited patient-centeredness and a traditional requirement for central adjudication. Days alive and out of the hospital (DAOH) has the potential to provide additional insight. Methods and Results TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) was a randomized, multinational clinical trial that compared the effect of prasugrel versus clopidogrel in patients stabilized after non-ST segment elevation acute coronary syndrome treated without revascularization; the trial had a neutral result. DAOH was calculated for each patient using site-submitted adverse event reporting data. We described patterns of DAOH overall, and among younger adults (<75 years old), older adults (≥75 years old), and frail/prefrail patients over 12 months follow-up and used Poisson regression to compare DAOH for patients randomized to prasugrel versus clopidogrel. Of 9249 patients in the overall trial population, 500 (5.4%) died, and 2504 (27.1%) were hospitalized 4150 times over 12 months' follow-up; the mean±SD DAOH was 317±86. The distribution of DAOH over 12 months was left-skewed, with median DAOH 363 days. Among younger adults, older adults, and frail/prefrail patients, mean DAOH were 323, 293, and 304 days, respectively. There were no differences in DAOH by treatment arm in the overall population (rate ratio, 1.00; 95% CI, 0.99-1.01) or any subgroup. Conclusions These results support the feasibility of determining DAOH, a patient-centered outcome that can potentially overcome many of the disadvantages of the traditional time-to-composite-event framework in the clinical trial setting. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT00699998.

Entities:  

Keywords:  acute coronary syndromes; clinical trial; clopidogrel; hospital; patients; stroke

Mesh:

Substances:

Year:  2018        PMID: 30562068      PMCID: PMC6347414          DOI: 10.1161/CIRCOUTCOMES.118.004755

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  33 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Authors:  Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

Review 3.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.

Authors:  Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

Review 4.  The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease.

Authors:  W Schuyler Jones; Matthew T Roe; Elliott M Antman; Mark J Pletcher; Robert A Harrington; Russell L Rothman; William J Oetgen; Sunil V Rao; Mitchell W Krucoff; Lesley H Curtis; Adrian F Hernandez; Frederick A Masoudi
Journal:  J Am Coll Cardiol       Date:  2016-10-25       Impact factor: 24.094

Review 5.  Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.

Authors:  Chirag Bavishi; Sadik Panwar; Franz H Messerli; Sripal Bangalore
Journal:  Am J Cardiol       Date:  2015-06-04       Impact factor: 2.778

6.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

7.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

Authors:  Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

Review 9.  New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.

Authors:  Jonas Oldgren; Lars Wallentin; John H Alexander; Stefan James; Birgitta Jönelid; Gabriel Steg; Johan Sundström
Journal:  Eur Heart J       Date:  2013-03-06       Impact factor: 29.983

10.  Characteristics of nondisabled older patients developing new disability associated with medical illnesses and hospitalization.

Authors:  Stefano Volpato; Graziano Onder; Margherita Cavalieri; Gianluca Guerra; Fotini Sioulis; Cinzia Maraldi; Giovanni Zuliani; Renato Fellin
Journal:  J Gen Intern Med       Date:  2007-03-01       Impact factor: 5.128

View more
  8 in total

1.  Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.

Authors:  Renato D Lopes; Ariane V S Macedo; Pedro G M de Barros E Silva; Renata J Moll-Bernardes; Tiago M Dos Santos; Lilian Mazza; André Feldman; Guilherme D'Andréa Saba Arruda; Denílson C de Albuquerque; Angelina S Camiletti; Andréa S de Sousa; Thiago C de Paula; Karla G D Giusti; Rafael A M Domiciano; Márcia M Noya-Rabelo; Alan M Hamilton; Vitor A Loures; Rodrigo M Dionísio; Thyago A B Furquim; Fábio A De Luca; Ítalo B Dos Santos Sousa; Bruno S Bandeira; Cleverson N Zukowski; Ricardo G G de Oliveira; Noara B Ribeiro; Jeffer L de Moraes; João L F Petriz; Adriana M Pimentel; Jacqueline S Miranda; Bárbara E de Jesus Abufaiad; C Michael Gibson; Christopher B Granger; John H Alexander; Olga F de Souza
Journal:  JAMA       Date:  2021-01-19       Impact factor: 56.272

2.  Real-life outcomes and readmissions after a TAVI procedure in a Glasgow population.

Authors:  Joanna Osmanska; David Murdoch
Journal:  Br J Cardiol       Date:  2021-09-01

3.  Characterization of "ICU-30": A Binary Composite Outcome for Neonates With Critical Congenital Heart Disease.

Authors:  Monique M Gardner; Garrett Keim; Jill Hsia; Anh D Mai; J William Gaynor; Andrew C Glatz; Nadir Yehya
Journal:  J Am Heart Assoc       Date:  2022-06-14       Impact factor: 6.106

4.  Computerized Electronic Order Set: Use and Outcomes for Heart Failure Following Hospitalization.

Authors:  Robert J H Miller; Alexandra Bell; Sandeep Aggarwal; James Eisner; Jonathan G Howlett
Journal:  CJC Open       Date:  2020-06-26

5.  Days out of Institution after Tracheostomy and Gastrostomy Placement in Critically Ill Older Adults.

Authors:  Anica C Law; Jennifer P Stevens; Eunhee Choi; Changyu Shen; Anuj B Mehta; Robert W Yeh; Allan J Walkey
Journal:  Ann Am Thorac Soc       Date:  2022-03

6.  Progressive multifocal leukoencephalopathy and Creutzfeldt-Jakob disease: population-wide incidences, comorbidities, costs of care, and outcomes.

Authors:  J A Bakal; C L Charlton; B Hlavay; G H Jansen; L W Svenson; C Power
Journal:  J Neurovirol       Date:  2021-05-12       Impact factor: 2.643

7.  Using routine healthcare data to evaluate the impact of the Medicines at Transitions Intervention (MaTI) on clinical outcomes of patients hospitalised with heart failure: protocol for the Improving the Safety and Continuity Of Medicines management at Transitions of care (ISCOMAT) cluster randomised controlled trial with embedded process evaluation, health economics evaluation and internal pilot.

Authors:  Lauren A Moreau; Ivana Holloway; Beth Fylan; Suzanne Hartley; Bonnie Cundill; Alison Fergusson; Sarah Alderson; David Phillip Alldred; Chris Bojke; Liz Breen; Hanif Ismail; Peter Gardner; Ellen Mason; Catherine Powell; Jonathan Silcock; Andrew Taylor; Amanda Farrin; Chris Gale
Journal:  BMJ Open       Date:  2022-04-29       Impact factor: 3.006

8.  Hospital-Free Days: A Pragmatic and Patient-centered Outcome for Trials among Critically and Seriously Ill Patients.

Authors:  Catherine L Auriemma; Stephanie P Taylor; Michael O Harhay; Katherine R Courtright; Scott D Halpern
Journal:  Am J Respir Crit Care Med       Date:  2021-10-15       Impact factor: 30.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.